Akrimax Pharmaceuticals, LLC

akrimax.com

At Akrimax Pharmaceuticals, we manufacture and market pharmaceutical products with unique and meaningful clinical advantages that improve the lives of patients. Our current commercial portfolio is focused in the areas of cardiovascular medicine, endocrinology and pain management. Akrimax is a sales and marketing company. Our mission is to acquire and commercialize under-promoted, under-utilized pharmaceutical products and those in late stage clinical development.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMACY MARKET, PHARMA TECH

MTTI OBTAINS FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG (IND) FOR HÜRTHLE CELL THYROID CANCER

Molecular Targeting Technologies, Inc | December 09, 2022

news image

Molecular Targeting Technologies, Inc. a clinical stage radiopharmaceutical therapy company focused on therapies for rare diseases, announced today the allowance of an Investigational New Drug application by the U.S. Food and Drug Administration. It is now waiting for Institutional Review Board approval. Once approved by IRB, it will enable a Phase I/II clinical study of the Safety, Dosimetry and Efficacy of EBTATE in adult patients with metastatic, radioactive iodine non-responsive Hürthle...

Read More

Pharma Tech

ASTRAZENECA, DAIICHI SANKYO PUSH ENHERTU CLOSER TO THE BLOCKBUSTER FRONTIER WITH STOMACH CANCER

Daiichi | January 20, 2021

news image

Daiichi Sankyo and partner AstraZeneca have taken their HER2-targeted cancer drug Enhertu another step toward blockbusterland. The FDA cleared Enhertu for HER2-positive gastric or gastroesophageal junction cancer patients who previously received Roche’s standard-of-care Herceptin, the companies said Monday. An antibody-drug conjugate, Enhertu is the first HER2-directed therapy approved in gastric cancer in a decade, the companies said. And it earned the green ...

Read More

Pharmacy Market

REALM IDX LAUNCHES REALM PHARMA SERVICES TO IMPROVE DRUG DEVELOPMENT AND RESEARCH

Businesswire | June 02, 2023

news image

REALM IDx announced the launch of REALM Pharma Services, an end-to-end discovery, translational research, and clinical trial service for biotechnology and pharmaceutical partners. Through a strategic integration, REALM Pharma Services brings together the research arms of subsidiaries, Ambry Genetics and Invicro, to offer cutting-edge genomics, traditional and molecular pathology, and advanced imaging and spatial biology. Combined with machine learning and artificial intelligence (AI) from ...

Read More

Business Insights, PHARMACY MARKET

HOVIONE AND H&T PRESSPART EXTEND PARTNERSHIP TO ADVANCE HIGH EFFICIENCY DEVICE TECHNOLOGY FOR DRY POWDER INHALATION FORMULATION DELIVERY

PRNewswire | May 04, 2023

news image

Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and H&T Presspart have entered in a strategic partnership to advance the development of Presspart's Sunriser© Capsule-based Dry Powder Inhaler platform. The demand for inhalable drugs that require higher drug loads and the delivery of cohesive materials has increased, making it necessary to develop more efficient solutions. To meet this demand, the two companies will work together to deve...

Read More
news image

PHARMACY MARKET, PHARMA TECH

MTTI OBTAINS FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG (IND) FOR HÜRTHLE CELL THYROID CANCER

Molecular Targeting Technologies, Inc | December 09, 2022

Molecular Targeting Technologies, Inc. a clinical stage radiopharmaceutical therapy company focused on therapies for rare diseases, announced today the allowance of an Investigational New Drug application by the U.S. Food and Drug Administration. It is now waiting for Institutional Review Board approval. Once approved by IRB, it will enable a Phase I/II clinical study of the Safety, Dosimetry and Efficacy of EBTATE in adult patients with metastatic, radioactive iodine non-responsive Hürthle...

Read More
news image

Pharma Tech

ASTRAZENECA, DAIICHI SANKYO PUSH ENHERTU CLOSER TO THE BLOCKBUSTER FRONTIER WITH STOMACH CANCER

Daiichi | January 20, 2021

Daiichi Sankyo and partner AstraZeneca have taken their HER2-targeted cancer drug Enhertu another step toward blockbusterland. The FDA cleared Enhertu for HER2-positive gastric or gastroesophageal junction cancer patients who previously received Roche’s standard-of-care Herceptin, the companies said Monday. An antibody-drug conjugate, Enhertu is the first HER2-directed therapy approved in gastric cancer in a decade, the companies said. And it earned the green ...

Read More
news image

Pharmacy Market

REALM IDX LAUNCHES REALM PHARMA SERVICES TO IMPROVE DRUG DEVELOPMENT AND RESEARCH

Businesswire | June 02, 2023

REALM IDx announced the launch of REALM Pharma Services, an end-to-end discovery, translational research, and clinical trial service for biotechnology and pharmaceutical partners. Through a strategic integration, REALM Pharma Services brings together the research arms of subsidiaries, Ambry Genetics and Invicro, to offer cutting-edge genomics, traditional and molecular pathology, and advanced imaging and spatial biology. Combined with machine learning and artificial intelligence (AI) from ...

Read More
news image

Business Insights, PHARMACY MARKET

HOVIONE AND H&T PRESSPART EXTEND PARTNERSHIP TO ADVANCE HIGH EFFICIENCY DEVICE TECHNOLOGY FOR DRY POWDER INHALATION FORMULATION DELIVERY

PRNewswire | May 04, 2023

Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and H&T Presspart have entered in a strategic partnership to advance the development of Presspart's Sunriser© Capsule-based Dry Powder Inhaler platform. The demand for inhalable drugs that require higher drug loads and the delivery of cohesive materials has increased, making it necessary to develop more efficient solutions. To meet this demand, the two companies will work together to deve...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us